Design, synthesis, and molecular docking study of novel quinoline‐based bis‐chalcones as potential antitumor agents
Abstract A novel series of quinoline‐based symmetrical and unsymmetrical bis‐chalcones was synthesized via a Claisen–Schmidt condensation reaction between 3‐formyl‐quinoline/quinolone derivatives with acetone or arylidene acetones, respectively, by using KOH/MeOH/H2 O as a reaction medium. Twelve of the obtained compounds were evaluated for their in vitro cytotoxic activity against 60 different human cancer cell lines according to the National Cancer Institute protocol. Among the screened compounds, the symmetrical N‐butyl bis‐quinolinyl‐chalcone14g and the unsymmetrical quinolinyl‐ bis‐chalcone17o bearing a 7‐chloro‐substitution on the N‐benzylquinoline moiety and 4‐hydroxy‐3‐methoxy substituent on the phenyl ring, respectively, exhibited the highest overall cytotoxicity against the evaluated cell lines with a GI50 range of 0.16–5.45 µM, with HCT‐116 (GI50 = 0.16) and HT29 (GI50 = 0.42 μM) (colon cancer) representing best‐case scenarios. Notably, several GI50 values for these compounds were lower than those of the reference drugs doxorubicin and 5‐FU. Docking studies performed on selected derivatives yielded very good binding energies in the active site of proteins that participate in key carcinogenic pathways..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:354 |
|---|---|
| Enthalten in: |
Archiv der Pharmazie - 354(2021), 9 |
| Beteiligte Personen: |
Insuasty, Daniel [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Deutsche Pharmazeutische Gesellschaft |
|---|
| Umfang: |
20 |
|---|
| doi: |
10.1002/ardp.202100094 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002403722 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002403722 | ||
| 003 | DE-627 | ||
| 005 | 20230307115133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ardp.202100094 |2 doi | |
| 028 | 5 | 2 | |a ARDP_ARDP202100094.xml |
| 035 | |a (DE-627)WLY002403722 | ||
| 035 | |a (WILEY)ARDP202100094 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Insuasty, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design, synthesis, and molecular docking study of novel quinoline‐based bis‐chalcones as potential antitumor agents |
| 264 | 1 | |c 2021 | |
| 300 | |a 20 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Deutsche Pharmazeutische Gesellschaft | ||
| 520 | |a Abstract A novel series of quinoline‐based symmetrical and unsymmetrical bis‐chalcones was synthesized via a Claisen–Schmidt condensation reaction between 3‐formyl‐quinoline/quinolone derivatives with acetone or arylidene acetones, respectively, by using KOH/MeOH/H2 O as a reaction medium. Twelve of the obtained compounds were evaluated for their in vitro cytotoxic activity against 60 different human cancer cell lines according to the National Cancer Institute protocol. Among the screened compounds, the symmetrical N‐butyl bis‐quinolinyl‐chalcone14g and the unsymmetrical quinolinyl‐ bis‐chalcone17o bearing a 7‐chloro‐substitution on the N‐benzylquinoline moiety and 4‐hydroxy‐3‐methoxy substituent on the phenyl ring, respectively, exhibited the highest overall cytotoxicity against the evaluated cell lines with a GI50 range of 0.16–5.45 µM, with HCT‐116 (GI50 = 0.16) and HT29 (GI50 = 0.42 μM) (colon cancer) representing best‐case scenarios. Notably, several GI50 values for these compounds were lower than those of the reference drugs doxorubicin and 5‐FU. Docking studies performed on selected derivatives yielded very good binding energies in the active site of proteins that participate in key carcinogenic pathways. | ||
| 700 | 1 | |a García, Stephanie |4 aut | |
| 700 | 1 | |a Abonia, Rodrigo |4 aut | |
| 700 | 1 | |a Insuasty, Braulio |4 aut | |
| 700 | 1 | |a Quiroga, Jairo |4 aut | |
| 700 | 1 | |a Nogueras, Manuel |4 aut | |
| 700 | 1 | |a Cobo, Justo |4 aut | |
| 700 | 1 | |a Borosky, Gabriela L. |4 aut | |
| 700 | 1 | |a Laali, Kenneth K. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archiv der Pharmazie |g 354(2021), 9 |w (DE-627)WLY002400111 |x 15214184 |7 nnns |
| 773 | 1 | 8 | |g volume:354 |g year:2021 |g number:9 |g extent:20 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 354 |j 2021 |e 9 |g 20 | ||